tiprankstipranks
Advertisement
Advertisement

RCUS Stock Latest News

Arcus Biosciences announces publication on ARC-20 study research
The FlyArcus Biosciences announces publication on ARC-20 study research
4d ago
RCUS
Arcus Biosciences Opens New Front With First-In-Human Trial of AB102
PremiumCompany Announcements
Arcus Biosciences Opens New Front With First-In-Human Trial of AB102
10d ago
RCUS
Arcus Biosciences Stockholders Back Directors and Governance Measures
PremiumCompany Announcements
Arcus Biosciences Stockholders Back Directors and Governance Measures
23d ago
8K
RCUS
Arcus Biosciences Advances Casdatifan With New Phase 1 Bioequivalence Study
PremiumCompany Announcements
Arcus Biosciences Advances Casdatifan With New Phase 1 Bioequivalence Study
24d ago
RCUS
Arcus Biosciences initiated with an Outperform at LifeSci Capital
PremiumThe Fly
Arcus Biosciences initiated with an Outperform at LifeSci Capital
1M ago
RCUS
Analyst Initiates Buy on Arcus Biosciences, Citing Best-in-Class HIF-2α Inhibitor Casdatifan and Expanded ccRCC Opportunity After Merck Setbacks
PremiumRatingsAnalyst Initiates Buy on Arcus Biosciences, Citing Best-in-Class HIF-2α Inhibitor Casdatifan and Expanded ccRCC Opportunity After Merck Setbacks
1M ago
RCUS
Arcus enters clinical trial collaboration, supply agreement with Bristol Myers
Premium
The Fly
Arcus enters clinical trial collaboration, supply agreement with Bristol Myers
1M ago
BMY
RCUS
Arcus Biosciences assumed with a Buy at Truist
Premium
The Fly
Arcus Biosciences assumed with a Buy at Truist
2M ago
RCUS
Arcus Biosciences price target raised to $22 from $20 at Morgan Stanley
PremiumThe Fly
Arcus Biosciences price target raised to $22 from $20 at Morgan Stanley
2M ago
RCUS
Arcus Biosciences Bets Big on Cascadifan
PremiumCompany Announcements
Arcus Biosciences Bets Big on Cascadifan
2M ago
RCUS
Arcus Advances Quemliclustat With Completed Phase 1 Metabolism Study
PremiumCompany Announcements
Arcus Advances Quemliclustat With Completed Phase 1 Metabolism Study
2M ago
RCUS
Arcus Biosciences rises 12.2%
PremiumThe Fly
Arcus Biosciences rises 12.2%
2M ago
RCUS
Merck setback has positives and negatives for Arcus Biosciences, says BofA
PremiumThe FlyMerck setback has positives and negatives for Arcus Biosciences, says BofA
2M ago
MRK
RCUS
Merck study miss not a read for Arcus, says H.C. Wainwright
Premium
The Fly
Merck study miss not a read for Arcus, says H.C. Wainwright
2M ago
MRK
RCUS
Arcus Biosciences: Buy Rated on Pipeline Control, PD‑1 Backbone Validation, and Upside from Emerging I&I and RCC Programs
Premium
Ratings
Arcus Biosciences: Buy Rated on Pipeline Control, PD‑1 Backbone Validation, and Upside from Emerging I&I and RCC Programs
2M ago
RCUS
Balanced Risk Profile After TIGIT Failure and Gilead Exit Supports Neutral Stance on Arcus
PremiumRatings
Balanced Risk Profile After TIGIT Failure and Gilead Exit Supports Neutral Stance on Arcus
3M ago
RCUS
Arcus Biosciences discontinues Star-121 study with Gilead due to futility
PremiumThe Fly
Arcus Biosciences discontinues Star-121 study with Gilead due to futility
3M ago
GILD
RCUS
Arcus Biosciences price target lowered to $47 from $49 at Leerink
PremiumThe Fly
Arcus Biosciences price target lowered to $47 from $49 at Leerink
3M ago
GILD
RCUS
Arcus Ends Key Lung Cancer Trials in Gilead Partnership Reset
PremiumCompany Announcements
Arcus Ends Key Lung Cancer Trials in Gilead Partnership Reset
3M ago
8K
RCUS
Wedbush raises Arcus Biosciences price target to $41, adds to Best Ideas List
PremiumThe FlyWedbush raises Arcus Biosciences price target to $41, adds to Best Ideas List
3M ago
RCUS
Arcus Biosciences Announces COO Resignation and Transition Plan
Premium
Company Announcements
Arcus Biosciences Announces COO Resignation and Transition Plan
3M ago
8K
RCUS
Damora Therapeutics appoints Jennifer Jarrett as CEO
Premium
The Fly
Damora Therapeutics appoints Jennifer Jarrett as CEO
3M ago
DMRA
RCUS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >